BioScience Health Innovations (BHIC) Current Deferred Revenue (2023 - 2026)

BioScience Health Innovations (BHIC) has 4 years of Current Deferred Revenue data on file, last reported at $76749.0 in Q1 2026.

• Current Deferred Revenue for Q1 2026 came in at $76749.0, up 53.38% year-over-year; the trailing twelve-month figure through Mar 2026 was $76749.0 (up 53.38% YoY), and the FY2025 annual result was $136590.0, up 461.43% from the prior year.
• Current Deferred Revenue eased to $76749.0 in Q1 2026 per BHIC's latest filing, from $136590.0 in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $248659.0 in Q2 2025 and troughed at $3949.0 in Q4 2023.
• A 4-year average of $93043.6 and a median of $76749.0 in 2026 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2024 and 2026: Current Deferred Revenue jumped 516.08% in 2024, then soared 53.38% in 2026.
• A 4-year view of Current Deferred Revenue shows it stood at $3949.0 in 2023, then jumped by 516.08% to $24329.0 in 2024, then surged by 461.43% to $136590.0 in 2025, then sank by 43.81% to $76749.0 in 2026.
• Business Quant data shows BHIC's Current Deferred Revenue at $76749.0 in Q1 2026, $136590.0 in Q4 2025, and $110991.0 in Q3 2025.